India & Brazil Signs MoU for Pharma and Medical Products Regulation

India and Brazil on Saturday signed a MoU to strengthen cooperation in regulating pharmaceutical and medical products, marking a key move to deepen health sector ties.

The agreement was formalized at Hyderabad House between Central Drugs Standard Control Organisation and Brazilian Health Regulatory Agency.

The MoU was exchanged by ANVISA Director-President Leandro Safatle and India’s Ambassador to Brazil Dinesh Bhatia in the presence of Prime Minister Narendra Modi and Brazilian President Luiz Inacio Lula da Silva.

The India-Brazil MoU sets up a structured framework for cooperation and information exchange across medical product regulation. This includes pharmaceutical ingredients, drugs, biological products, and medical devices. The goal is to align regulatory practices, improve mutual understanding, and ensure coordinated oversight.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

According to the Ministry of Health and Family Welfare, the agreement reflects a shared commitment to delivering safe, effective, and quality-assured medicines. It is also expected to strengthen supply chains, promote best regulatory practices, and improve access to affordable healthcare.

The deal builds on existing India-Brazil cooperation in health and adds momentum to their broader partnership. Both countries have increasingly worked together in pharmaceuticals and medical technology, while advocating for the Global South.

Under the agreement, both sides will collaborate on information sharing, regulatory capacity building, and joint efforts in overseeing pharmaceutical and medical products, in line with their national laws.

This MoU is expected to open new pathways for collaboration, reinforce bilateral ties, and contribute to better public health outcomes in both nations.